J Neurocrit Care.  2023 Dec;16(2):119-122. 10.18700/jnc.230032.

Extremely elevated international normalized ratio in a patient using dabigatran etexilate: a case report

• Kim J
• Jung Y
• Oh J
• Han SW
• Yu Hj

• KMID: 2549491
• DOI: http://doi.org/10.18700/jnc.230032

Abstract

Background
We present the case of a patient who was administered dabigatran and showed an extremely elevated prothrombin time-international normalized ratio (PT-INR).
Case report
A 79-year-old man was referred due to PT-INR 12.6. The patient was taking 110 mg of dabigatran twice daily in capsule form. On admission, blood urea nitrogen level was 23 mg/dL, creatinine was 1.51 mg/dL, and the estimated glomerular filtration rate was 44.8 mL/min/1.73 m2. Coagulation tests revealed PT 96.8 seconds, PT-INR 12.46, and activated partial thromboplastin time 125.5 seconds. Dabigatran was discontinued, PT-INR on the day after admission was 8.96. PT-INR recovered to 1.61 on the fourth day without any treatment.
Conclusion
The PT-INR was not directly correlated with dabigatran activity. Regular monitoring of coagulation was not necessary in all patients taking dabigatran. However, it may be useful to regularly perform coagulation tests in patients with renal impairment or in those at a high risk of bleeding.

Keyword

Anticoagulants; Blood coagulation; International normalized ratio; Case report

Reference

1. Blair HA, Keating GM. Dabigatran etexilate: a review in nonvalvular atrial fibrillation. Drugs. 2017; 77:331–44.

2. Chan NC, Coppens M, Hirsh J, Ginsberg JS, Weitz JI, Vanassche T, et al. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost. 2015; 13:353–9.

3. Salem AM, Roh D, Kitagawa R, Choi HA, Chang TR. Assessment and management of coagulopathy in neurocritical care. J Neurocrit Care. 2019; 12:9–19.

4. Jung KH, Yu KH, Kim YD, Park JM, Hong KS, Rha JH, et al. Focused update of guidelines for antithrombotic management of patients with atrial fibrillation and ischemic stroke or transient ischemic attack. J Korean Neurol Assoc. 2016; 34:184–92.

5. Duan J, Yang L, Li H, Yamamura N, Harada A. Pharmacokinetics and safety of dabigatran etexilate after single and multiple oral doses in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 2020; 45:601–9.

6. Park H, Yoo J. Use of non-vitamin k dependent oral anticoagulant in ischemic stroke. J Korean Neurol Assoc. 2022; 40:1–14.

7. Kim J, Yadava M, An IC, Sayeed A, Laird-Fick HS, Gourineni V, et al. Coagulopathy and extremely elevated PT/INR after dabigatran etexilate use in a patient with end-stage renal disease. Case Rep Med. 2013; 2013:131395.

8. Korean Heart Rhythm Society. 2022 Korean Heart Rhythm Society Guidelines for Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) [Internet]. Korean Heart Rhythm Society; 2022 [cited 2023 Nov 20]. Available from: http://www.k-hrs.org/upload/2022%20Korean%20Arrhythmia%20Society_NOAC_Guidelines.pdf.

9. Vidal J, DePalma R, Forouzan L. Reversal of dabigatran bleeding and coagulopathy using idarucizumab in a patient with acute kidney injury. P T. 2018; 43:748–9.

10. Memon W, Aamir M, Memon A. Extremely elevated international normalized ratio in a patient with dabigatran etexilate use. Cureus. 2019; 11:e4906.

11. Cattaneo M, Chahil A, Somers D, Kinlough-Rathbone RL, Packham MA, Mustard JF. Effect of aspirin and sodium salicylate on thrombosis, fibrinolysis, prothrombin time, and platelet survival In rabbits with indwelling aortic catheters. Blood. 1983; 61:353–61.